Resources

If you need more information feel free to contact our Help Center

Featured

Deep Research: Causaly's Agentic AI is Unlocking a New Dimension of Scientific Discovery

As research continues to evolve, scientists need more. That’s why we’re excited about the upcoming release of Causaly Deep Research—the only agentic AI on the market built to help life sciences organizations achieve unmatched precision and tackle the deepest challenges in biomedical research.

Team Causaly
May 7, 2025
Read more
BlogNewsEvents & WebinarsCase studiesDownloads

Blog

Discover the latest reports, data sheets, articles, infographics, and videos on biomedical R&D and AI.

Disease Pathophysiology
Target selection
Safety
Biomarkers
causaly

Unraveling Mechanisms of Disease Pathogenesis with AI

Anna Tzani
March 6, 2024

AI-supported investigations into disease mechanisms offer a transformative approach to understand complex pathologies. By leveraging AI to unlock disease understanding, researchers can identify novel biomarkers and therapeutic targets with unprecedented precision. This not only accelerates the journey from lab to market but also enhances the efficacy and safety of new treatments.

Read more

Leveraging AI for Scientific Knowledge Extraction

Anna Tzani
February 13, 2024

AI is transforming the analysis of extensive biomedical data, allowing pharma companies to expedite R&D processes, and cut costs. By reaching conclusions quicker, the inclusion of AI in drug development pipelines can inform decision-making, enabling the prioritization of more promising research avenues.

Read more

Exploring the Disease Pathophysiology of Rheumatoid Arthritis

Anna Tzani
February 6, 2024

Understanding the pathophysiology of a disease is pivotal in comprehending its cause and progression and facilitating the identification of novel targets for therapeutic intervention. Data-driven strategies are essential in navigating this complexity, facilitating a deeper understanding of disease pathophysiology, which can be leveraged to develop more effective treatments.

Read more

Search by Target Class: Enzyme Targets for Celiac Disease

Anna Tzani
January 26, 2024

The strategic prioritization of drug targets by target class can be used to streamline discovery, enabling efficient resource allocation and time-savings in early drug development, as well as a competitive edge given the variable success rates of different target classes. Prioritization of specific target classes may therefore enable investment optimization in preclinical research.

Read more

Navigating the Biomedical Literature: Insights vs. Papers

Anna Tzani
January 19, 2024

With 2 publications added to PubMed every minute, identifying therapeutic targets with traditional keyword searching is time-consuming, causes reading fatigue and is subject to bias. By machine-reading the literature, Causaly manages this data overload, extracting scientific insights rather than papers, to enable the exploration of more novel avenues.

Read more

Uncovering the Mechanism of Action of Evolocumab against PAD

Anna Tzani
January 12, 2024

Deciphering a drug’s MoA is crucial for making informed decisions in drug development, paving the way for the development of more targeted and effective therapeutic solutions. AI can revolutionize this process by facilitating knowledge discovery without bias, unveiling hidden drug-disease interactions.

Read more

ProQR Uses Causaly to Support Target Identification For Axiomer™ Platform

Yiannis Kiachopoulos
January 28, 2025

ProQR faced challenges with bandwidth, aggressive targets, and the overwhelming growth of biomedical literature. Causaly's AI platform accelerated ProQR’s R&D by enabling faster review of publications and allowing their team to make more informed decisions. Read the case study below to learn how ProQR met their 2024 target ID goal by Q3 and achieved 5x productivity compared to using PubMed.

Read more

Enhance Your Search Sensitivity with AI: Off-Target Effects of BRAF

Anna Tzani
February 29, 2024

In contrast to conventional keyword searching techniques, Causaly’s AI can sift through and remove irrelevant data from biomedical searches, offering a more thorough and accurate understanding of entire research landscapes. This not only streamlines knowledge acquisition but ensures accuracy and precision in navigating the biomedical literature.

Read more

Leveraging AI for Scientific Knowledge Extraction

Anna Tzani
February 13, 2024

AI is transforming the analysis of extensive biomedical data, allowing pharma companies to expedite R&D processes, and cut costs. By reaching conclusions quicker, the inclusion of AI in drug development pipelines can inform decision-making, enabling the prioritization of more promising research avenues.

Read more

Search by Target Class: Enzyme Targets for Celiac Disease

Anna Tzani
January 26, 2024

The strategic prioritization of drug targets by target class can be used to streamline discovery, enabling efficient resource allocation and time-savings in early drug development, as well as a competitive edge given the variable success rates of different target classes. Prioritization of specific target classes may therefore enable investment optimization in preclinical research.

Read more

Navigating the Biomedical Literature: Insights vs. Papers

Anna Tzani
January 19, 2024

With 2 publications added to PubMed every minute, identifying therapeutic targets with traditional keyword searching is time-consuming, causes reading fatigue and is subject to bias. By machine-reading the literature, Causaly manages this data overload, extracting scientific insights rather than papers, to enable the exploration of more novel avenues.

Read more

Eliminating Bias with Human-Centric AI

Anna Tzani
January 9, 2024

Traditional keyword searching can miss crucial information, skewing representations of research landscapes before reading even begins. Instead, Causaly’s human-centric AI can extract all targets for a given disease without bias, uncovering scientific insights, rather than just papers.

Read more

Aiding Drug Repurposing Investigations with AI

Anna Tzani
February 23, 2024

Drug repurposing offers a cost-effective and efficient pathway to discovery new therapeutic uses for existing treatments. AI can advance this process by rapidly analyzing large-scale biomedical data and scientific texts to identify drug-disease relationships, opening up avenues for treatments in unexplored indications.

Read more

Comparison of Safety Biomarkers for Chemotherapeutics

Anna Tzani
February 9, 2024

The identification and utilization of safety biomarkers plays a key role in mitigating toxicity risks and reducing costs in drug development, thereby accelerating the delivery of safe and effective drugs to patients. AI can streamline the identification of relevant biomarkers from the ever-growing biomedical literature, offering insights into drug resistance and toxicity.

Read more

AI-Powered Drug Discovery: Identifying Safety Red Flags

Anna Tzani
January 30, 2024

Unmanageable toxicity accounts for 30% of clinical drug development failures and can cause severe side effects and potential harm to patients. Download our report to see how AI-powered drug discovery can help mitigate late-stage clinical failures and market withdrawals.

Read more

Comparison of Safety Biomarkers for Chemotherapeutics

Anna Tzani
February 9, 2024

The identification and utilization of safety biomarkers plays a key role in mitigating toxicity risks and reducing costs in drug development, thereby accelerating the delivery of safe and effective drugs to patients. AI can streamline the identification of relevant biomarkers from the ever-growing biomedical literature, offering insights into drug resistance and toxicity.

Read more

Challenging the Status Quo: A Biomarker Use Case

Anna Tzani
January 24, 2024

Traditional keyword searching is highly inefficient, subject to bias and is not always comprehensive, providing limited potential for knowledge discovery and hypothesis generation. This selective approach introduces a bias towards familiar areas of expertise, which can lead to missed opportunities for novel insights and innovations. This is where AI comes in.

Read more

Biomarkers of Treatment Response in Liver Cancer

Anna Tzani
December 7, 2023

Biomarkers serve as objective measures of treatment response to guide patients towards the most appropriate therapies. Yet, in the era of big data, pinpointing promising biomarkers remains a challenging endeavor. AI is revolutionizing translational medicine by improving the efficiency and accuracy of biomarker identification.

Read more

Expedite Biomarker Discovery with Human-Centric AI

Anna Tzani
December 4, 2023

Biomarkers are pivotal throughout drug development, from discovery to market, playing key roles in unravelling drug mechanisms, providing prognostic insights and assessing treatment efficacy. Despite the clinical promise, biomarker development is challenging. There are substantial obstacles, from disease heterogeneity and rigorous validation requirements to the inability to extract meaningful biomarker insights from extensive biological data.

Read more

Agentic AI: Unlocking deeper insights and accelerating scientific discovery

Team Causaly
May 20, 2025

An explosion in biomedical data has the potential to empower life sciences R&D teams. But only if they’re able to make sense of that data, rather than being overwhelmed by it. Which is where Agentic AI comes in — a new technology that can independently conduct research, suggest testable hypotheses, and dramatically reduce time-to-discovery.

Read more

Moving faster with more certainty: How AI can revolutionize life sciences R&D

May 20, 2025

How can R&D teams make the drug discovery process faster and more effective? To make real progress, traditional research methods won’t cut it. But a new era of AI can — specifically by helping researchers uncover complex biological relationships, generate new hypotheses, and find the right answer that leads to a breakthrough.

Read more

Deep Research: Causaly's Agentic AI is Unlocking a New Dimension of Scientific Discovery

Team Causaly
May 7, 2025

As research continues to evolve, scientists need more. That’s why we’re excited about the upcoming release of Causaly Deep Research—the only agentic AI on the market built to help life sciences organizations achieve unmatched precision and tackle the deepest challenges in biomedical research.

Read more

Causaly Discover: Transforming Scientific Research with Agentic AI

Team Causaly
March 31, 2025

Today, we're excited to introduce the latest version of Discover, not just as another literature search tool, but as a revolutionary AI application redefining how life sciences companies approach scientific discovery.

Read more

How Gen AI is Improving Productivity Across Life Sciences R&D Teams

Yiannis Kiachopoulos
October 29, 2024

The life sciences industry faces the challenge of managing vast amounts of data and coordinating diverse teams to efficiently translate scientific insights into tangible outcomes. Traditional research methods are time-consuming and limit productivity. Generative AI offers a transformative solution by accelerating hypothesis generation, enhancing data analysis, improving decision-making, and facilitating collaboration.

Read more

The Official 2024 Launch of Causaly Copilot

Yiannis Kiachopoulos
February 27, 2024

How we successfully went from experimentation to scale to build and launch a production-grade GenAI Copilot made for scientists

Read more
Read more

News

The latest news and updates from Causaly.

news

Causaly Announces Agentic AI for Scientific Discovery

Team Causaly
March 31, 2025

New AI agents in Causaly Discover empower scientists to answer complex biomedical questions faster and more accurately across a broader range of sources

Read more
news

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

Andrew Taylor
July 13, 2023

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Read more
news

Causaly announces ISO 27001 certification

Andrew Taylor
June 28, 2022

We are proud to announce a major milestone for Causaly: successfully passing ISO 27001 certification.

Read more
news

Causaly raises $17 million to accelerate biomedical research and discovery of scientific breakthroughs

Yiannis Kiachopoulos
May 19, 2021

Causaly, the London-based company that allows researchers and specialists to intuitively map and navigate the intricate landscape of biomedical research, has raised $17 million from investors to grow its team and expand into new markets.

Read more
news

Covid-19: Causaly partners with UCL to accelerate coronavirus research

Yiannis Kiachopoulos
April 21, 2020

At Causaly we’re excited to announce a new partnership with University College London (UCL) to help accelerate research into the pandemic.

Read more
news

Causaly raises $5m in Series A round led by Pentech Ventures

Yiannis Kiachopoulos
November 19, 2019

Causaly, the AI company that is teaching computers to read, understand and interpret all biomedical knowledge ever published, is pleased to announce its series A funding round, which saw new and existing investors commit $4.8m into the company. Pentech Ventures led the round together with EBRD Venture Capital, with participation from existing investors Marathon Venture Capital as well as existing angel investors.

Read more
Read more

Events and Webinars

Our events and webinars on demand and dig deeper into the next era of scientific research.

Webinar

Move from Simple Search to Transformative Insights with AI

No items found.
March 25, 2025

Join us for an exclusive webinar where we’ll showcase Causaly Discover, our latest AI-powered research application that transforms the way scientists carry out their research.

Watch now
Webinar

GenAI for R&D Organizations: From Experimentation to Scale

March 21, 2024

Discover how R&D organizations can evolve from AI conceptualization to transformative impact, focusing on strategies for large-scale adoption.

Watch now
Webinar

Transforming Early Stage Drug Discovery with LLMs Explore how scientists are integrating AI in preclinical research

February 15, 2024

Watch this insightful and hands-on webinar, where we walked through the most relevant AI trends for early research teams, addressing key concerns when adopting AI for pre-clinical research, and demonstrated how AI can be used to support your research.

Watch now
Webinar

Decoding the Future of Drug Discovery: More than just Associations: Knowledge Graphs, Causal Reasoning & Large Language Models

No items found.
October 20, 2023

Join us for an exclusive webinar during World AI Week to explore the transformative impact of AI on drug discovery.

Watch now
Event

Causaly Connect Live 2023

No items found.
October 10, 2023

Access at your convenience all the recordings of the presentations that were given at the Causaly Connect Conference in New York, October 2023.

Watch now
Webinar

AI for Enhanced Biomarker Discovery

June 20, 2023

Watch now our on-demand webinar to explore how human-centric AI is revolutionizing biomarker discovery in oncology and immunology.

Watch now
Read more

Case studies

Read our latest case studies and see how we’ve helped our customers.

Case studies

ProQR Uses Causaly to Support Target Identification For Axiomer™ Platform

ProQR
February 28, 2025
Read more
Read more

Downloads

The latest downloadable content from Causaly.

Download

Target Discovery Factsheet: Navigate the Target Landscape of Prostate Cancer

January 29, 2025
Read more
Download

Spotlight On Biomarkers Uncover the Latest Biomarkers of Disease Progression, Prediction and Survival

November 15, 2024
Read more
Download

Infographic: Target Discovery in Endocrinology

October 23, 2024
Read more
Read more
Causaly logo

Unlock scientific insights from external and internal information at unprecedented levels of precision and efficiency.

Get started
Login
Causaly
AboutRequest a demoContact usResourcesCareers
LEGAL
Privacy policy
Terms of service
Cookies settings
© Causaly. All rights reserved.